Biosimilar Cost, Utilization, and Pipeline

Published: March 16, 2022

2022 pbconference feature

– Review of approved biosimilars in the US and market share trends
– Initial, current, and future biosimilar management trends
– Physician and Pharma response to biosimilar agents
– Biosimilar interchangeability and Authorized Biologics
– Biosimilar products in the pipeline
– Patient and healthcare system impact

Author(s)/Presenter(s):

Leslie Fish, RPh, PharmD, Vice President of Clinical Pharmacy, IPD Analytics, LLC

Jeffrey Casberg, MS, RPh, Vice President of Clinical Pharmacy, IPD Analytics, LLC

View All Resources